YatPui Au - Regencell Bioscience Chief Officer
| RGC Stock | USD 5.65 0.05 0.88% |
Executive
YatPui Au is Chief Officer of Regencell Bioscience Holdings
| Age | 50 |
| Address | Chinachem Leighton Plaza, Causeway Bay, Hong Kong |
| Phone | 852 2155 0823 |
| Web | https://www.regencellbioscience.com |
Regencell Bioscience Management Efficiency
The company has Return on Asset of (0.2811) % which means that on every $100 spent on assets, it lost $0.2811. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4318) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Return On Equity is projected to grow to (0.13). At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Malek Chamoun | Sunshine Biopharma Warrant | 39 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Christine CPA | Prestige Brand Holdings | 48 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Nikolaos Bardakis | Cosmos Health | 55 | |
| Glenn David | Phibro Animal Health | 52 | |
| Christopher Mutz | ANI Pharmaceuticals | 53 | |
| Jose Vieira | Procaps Group SA | 58 | |
| Carlos Russo | Procaps Group SA | 39 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Marc Beaudoin | Sunshine Biopharma Warrant | 57 | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Camilo Camacho | Procaps Group SA | 50 | |
| Larry Miller | Phibro Animal Health | 60 | |
| James Marken | ANI Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 |
Regencell Bioscience Leadership Team
Elected by the shareholders, the Regencell Bioscience's board of directors comprises two types of representatives: Regencell Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regencell. The board's role is to monitor Regencell Bioscience's management team and ensure that shareholders' interests are well served. Regencell Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regencell Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wai Chung, COO Officer | ||
| Tien Chau, Executive Officer | ||
| YiChung Chao, Special Director | ||
| Michelle Chan, Financial Controller | ||
| YatPui Au, Chief Officer | ||
| YatGai Au, Chairman Founder | ||
| Antonia Assang, Senior Management |
Regencell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regencell Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 65.65 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Shares Owned By Insiders | 88.81 % | ||||
| Shares Owned By Institutions | 0.19 % | ||||
| Number Of Shares Shorted | 62.16 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 8.95 X | ||||
| EBITDA | (3.62 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.